Table 2.
SARS-CoV-2 exposure and symptoms.
| Characteristic | All (n = 655) |
Spondyloarthritis (n = 474) |
Rheumatoid arthritis (n = 129) |
Psoriatic arthritis (n = 52) |
|---|---|---|---|---|
| Exposure, at least one, n (%) | 211 (33.2) | 170 (35.9) | 30 (23.2) | 11 (21.1) |
| Contact with a traveler in high incidence countrya, n (%) | 83 (12.7) | 70 (14.8) | 9 (7.0) | 4 (7.7) |
| Contact with a confirmed case, n (%) | 58 (8.9) | 49 (10.4) | 6 (4.7) | 3 (5.8) |
| Contact with a suspected case, n (%) | 153 (23.4) | 125 (26.4) | 20 (15.5) | 8 (15.4) |
| Travel in a high incidence countrya, n (%) | 35 (5.3) | 28 (5.9) | 6 (4.7) | 1 (1.9) |
| Symptoms, at least one, n (%) | 388 (59.2) | 290 (61.2) | 67 (51.9) | 31 (59.6) |
| Headache, n (%) | 201 (30.7) | 157 (33.1) | 25 (19.4) | 19 (36.5) |
| Rhinorrhea, n (%) | 147 (22.5) | 106 (22.4) | 25 (19.4) | 16 (30.8) |
| Dry cough, n (%) | 123 (18.8) | 101 (21.3) | 16 (12.4) | 6 (11.5) |
| Fever, n (%) | 117 (17.9) | 89 (18.8) | 17 (13.2) | 11 (21.1) |
| Myalgia, n (%) | 115 (17.6) | 91 (19.3) | 15 (11.6) | 9 (17.3) |
| Diarrhea, n (%) | 106 (16.2) | 87 (18.3) | 12 (9.3) | 7 (13.5) |
| Chills, n (%) | 104 (15.9) | 77 (16.2) | 13 (10.1) | 14 (26.9) |
| Thoracic pain, n (%) | 90 (13.8) | 76 (16.0) | 9 (7.0) | 5 (9.6) |
| Dyspnea, n (%) | 87 (13.3) | 66 (14.0) | 15 (11.6) | 6 (11.5) |
| Abdominal pain, n (%) | 84 (12.8) | 70 (14.8) | 8 (6.2) | 6 (11.5) |
| Wet cough, n (%) | 77 (11.8) | 54 (11.4) | 17 (13.2) | 6 (11.5) |
| Nausea, vomiting, n (%) | 52 (8.0) | 37 (7.8) | 9 (7.0) | 6 (11.5) |
| Skin lesions, n (%) | 30 (4.6) | 26 (5.5) | 3 (2.3) | 1 (1.9) |
| Confusion, n (%) | 27 (4.1) | 22 (4.7) | 5 (3.9) | 0 (0) |
| Agueusia, n (%) | 14 (2.1) | 7 (1.5) | 5 (3.9) | 2 (3.9) |
| Anosmia, n (%) | 11 (1.7) | 6 (1.3) | 4 (3.1) | 1 (1.9) |
a
High incidence countries: China, Hong-Kong, Italy, Spain.